摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

8-hydroxy-5-[1-hydroxy-2-(indan-2-yl-amino)-ethyl]-1H-quinolin-2-one

中文名称
——
中文别名
——
英文名称
8-hydroxy-5-[1-hydroxy-2-(indan-2-yl-amino)-ethyl]-1H-quinolin-2-one
英文别名
8-Hydroxy-5-[1-hydroxy-2-(indan-2-ylamino)-ethyl]-1h-quinolin-2-one;5-[2-(2,3-dihydro-1H-inden-2-ylamino)-1-hydroxyethyl]-8-hydroxy-1H-quinolin-2-one
8-hydroxy-5-[1-hydroxy-2-(indan-2-yl-amino)-ethyl]-1H-quinolin-2-one化学式
CAS
——
化学式
C20H20N2O3
mdl
——
分子量
336.39
InChiKey
HHEMVSCLLFFBQM-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.8
  • 重原子数:
    25
  • 可旋转键数:
    4
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.25
  • 拓扑面积:
    81.6
  • 氢给体数:
    4
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] BETA2-ADRENOCEPTOR AGONISTS<br/>[FR] AGONISTES DU RECEPTEUR BETA 2-ADRENERGIQUE
    申请人:NOVARTIS AG
    公开号:WO2000075114A1
    公开(公告)日:2000-12-14
    Compounds of formula (I) in free or salt or solvate form, where Ar is a group of formula (II) Y is carbon or nitrogen and R?1, R2, R3, R4, R5, R6, R7, R8, R9, R10¿, X, n, p, q and r are as defined in the specification, their preparation and their use as pharmaceuticals, particularly for the treatment of obstructive or inflammatory airways diseases. The compounds of formula (I) in free, salt or solvate form, have β2-adrenoreceptor agonist activity.
    公式(I)的化合物,其自由形式、盐形式或溶剂化合物形式中,其中Ar是公式(II)的基团,Y是碳或氮,R?1,R2,R3,R4,R5,R6,R7,R8,R9,R10,X,n,p,q和r如规范所定义,它们的制备以及它们作为药物的用途,特别是用于治疗阻塞性或炎性呼吸道疾病。公式(I)的化合物在自由、盐或溶剂化合物形式中具有β2-肾上腺素受体激动剂活性。
  • QUINOLINONE DERIVATIVES AND THEIR PHARMACEUTICAL COMPOSITIONS
    申请人:Lohse Olivier
    公开号:US20090325912A1
    公开(公告)日:2009-12-31
    Compounds of formula I in salt or solvate form, wherein W, R x , R y , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 and A have the meanings as indicated in the specification, are useful for treating diseases mediated by the β 2 -adrenoreceptor. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
    化合物I的盐或溶剂形式,其中W,Rx,Ry,R1,R2,R3,R4,R5,R6和R7以及A的含义如规范中所示,可用于治疗由β2-肾上腺素受体介导的疾病。还描述了含有这些化合物的药物组成物以及制备这些化合物的过程。
  • BETA-2-ADRENORECEPTOR AGONISTS
    申请人:Cuenoud Bernard
    公开号:US20100029705A1
    公开(公告)日:2010-02-04
    Compounds of formula in free or salt or solvate form, where Ar is a group of formula Y is carbon or nitrogen and R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , X, n, p, q and r are as defined in the specification, their preparation and their use as pharmaceuticals, particularly for the treatment of obstructive or inflammatory airways diseases.
    该化合物的化学式为自由或盐或溶剂形式,其中Ar是化学式的一组,Y是碳或氮,R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、X、n、p、q和r的定义在说明书中,其制备以及其作为药物的用途,特别是用于治疗阻塞性或炎症性呼吸道疾病。
  • Beta-2-Adrenoreceptor Agonists
    申请人:Cuenoud Bernard
    公开号:US20120077838A1
    公开(公告)日:2012-03-29
    Compounds of formula in free or salt or solvate form, where Ar is a group of formula Y is carbon or nitrogen and R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , X, n, p, q and r are as defined in the specification, their preparation and their use as pharmaceuticals, particularly for the treatment of obstructive or inflammatory airways diseases.
    该化合物的化学式为自由或盐或溶剂形式,其中Ar是公式的一组,Y为碳或氮,R1,R2,R3,R4,R5,R6,R7,R8,R9,R10,X,n,p,q和r如规范所定义,它们的制备以及它们作为药物的用途,特别是用于治疗阻塞性或炎症性呼吸道疾病。
  • beta-2-Adrenoreceptor Agonists
    申请人:Cuenoud Bernard
    公开号:US20120302531A1
    公开(公告)日:2012-11-29
    Compounds of formula in free or salt or solvate form, where Ar is a group of formula Y is carbon or nitrogen and R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , X, n, p, q and r are as defined in the specification, their preparation and their use as pharmaceuticals, particularly for the treatment of obstructive or inflammatory airways diseases.
    该化合物的分子式可以是自由形式、盐形式或溶剂形式,其中Ar是化学式的一组,Y是碳或氮,而R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、X、n、p、q和r的定义在说明书中,其制备及其作为药物的用途,特别是用于治疗阻塞性或炎症性气道疾病。
查看更多